

# Claudia Rossig

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6545529/claudia-rossig-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86

papers

4,368

citations

29

h-index

65

g-index

96

ext. papers

5,162

ext. citations

6.4

avg, IF

4.89

L-index

#	Paper	IF	Citations
86	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. <i>Nature Medicine</i> , <b>2008</b> , 14, 1264-70	50.5	919
85	Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. <i>Blood</i> , <b>2011</b> , 118, 6050-6	2.2	813
84	Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. <i>Blood</i> , <b>2002</b> , 99, 3179-87	2.2	267
83	Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. <i>Blood</i> , <b>2002</b> , 99, 2009-16	2.2	168
82	Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. <i>Leukemia</i> , <b>2006</b> , 20, 1819-28	10.7	157
81	2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4857-66	12.9	141
80	Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. <i>International Journal of Cancer</i> , <b>2001</b> , 94, 228-36	7.5	126
79	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 884-892	10.7	119
78	The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1123-33	8.7	84
77	Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3065-71	2.2	77
76	Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. <i>British Journal of Haematology</i> , <b>2004</b> , 126, 583-92	4.5	73
75	Genetic modification of T lymphocytes for adoptive immunotherapy. <i>Molecular Therapy</i> , <b>2004</b> , 10, 5-18	11.7	70
74	Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. <i>Oncotmunology</i> , <b>2017</b> , 6, e1250050	7.2	65
73	PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 317-320	4.4	62
72	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3499-3509	12.9	52
71	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4935-46	12.9	49
70	Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2017</b> , 31, 1087-1095	10.7	47

69	Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1574-81	3	47
68	A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 879-86	7.5	44
67	NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. <i>Leukemia</i> , <b>2012</b> , 26, 465-74	10.7	44
66	Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. <i>Cancer Research</i> , <b>2006</b> , 66, 24-8	10.1	37
65	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 77	7	36
64	Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. <i>Leukemia</i> , <b>2016</b> , 30, 970-3	10.7	35
63	EZH2 Inhibition in Ewing Sarcoma Upregulates G Expression for Targeting with Gene-Modified T Cells. <i>Molecular Therapy</i> , <b>2019</b> , 27, 933-946	11.7	35
62	2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 1991-2001	7.4	34
61	Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26719	3	33
60	Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-G CAR Expression and Inducible Cytokines. <i>Cancers</i> , <b>2020</b> , 12,	6.6	32
59	FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6227-6238	12.9	30
58	Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. <i>Oncotarget</i> , <b>2017</b> , 8, 108584-108603	3.3	29
57	Activated human $\alpha$ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 385-96	7.4	28
56	Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 310-21	5	28
55	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. <i>Oncotarget</i> , <b>2018</b> , 9, 6536-6549	3.3	28
54	Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. <i>Cancers</i> , <b>2020</b> , 12,	6.6	27
53	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , <b>2020</b> , 127, 52-66	7.5	26
52	Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. <i>Cancer Research</i> , <b>2007</b> , 67, 8335-43	10.1	26

51	Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. <i>Gene Therapy</i> , <b>2016</b> , 23, 615-26	4	26
50	Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. <i>Journal of Immunotherapy</i> , <b>2006</b> , 29, 21-31	5	25
49	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. <i>BMC Cancer</i> , <b>2019</b> , 19, 895	4.8	23
48	Adoptive cellular immunotherapy with CD19-specific T cells. <i>Klinische Padiatrie</i> , <b>2005</b> , 217, 351-6	0.9	23
47	Aetiology of childhood acute leukaemias: current status of knowledge. <i>Radiation Protection Dosimetry</i> , <b>2008</b> , 132, 114-8	0.9	21
46	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 513	5.3	21
45	Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 658-66	8.7	20
44	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). <i>Blood</i> , <b>2021</b> , 137, 1582-1590	2.2	19
43	SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3718-3729	1.9	18
42	Effective combination treatment of GD2-expressing neuroblastoma and Ewing sarcoma using anti-GD2 ch14.18/CHO antibody with VβVα+ T cells. <i>Onc Immunology</i> , <b>2016</b> , 5, e1025194	7.2	18
41	Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. <i>Haematologica</i> , <b>2019</b> , 104, 120-127	6.6	17
40	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 834-844	6.1	16
39	Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. <i>Oncology Reports</i> , <b>2014</b> , 32, 845-52	3.5	15
38	CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. <i>Clinical and Experimental Immunology</i> , <b>2006</b> , 144, 447-57	6.2	14
37	Requirement for YAP1 signaling in myxoid liposarcoma. <i>EMBO Molecular Medicine</i> , <b>2019</b> , 11,	12	13
36	Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. <i>Sarcoma</i> , <b>2016</b> , 2016, 7461783	3.1	13
35	Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 1047-60	7.4	12
34	CAR T cell immunotherapy in hematology and beyond. <i>Clinical Immunology</i> , <b>2018</b> , 186, 54-58	9	10

33	High proportions of CD4+ T cells among residual bone marrow T cells in childhood acute lymphoblastic leukemia are associated with favorable early responses. <i>Acta Haematologica</i> , <b>2014</b> , 131, 28-36	2.7	10
32	VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28313	3	10
31	Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 692-5		9
30	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. <i>European Journal of Cancer</i> , <b>2020</b> , 141, 82-91	7.5	9
29	New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology. <i>Pediatric Hematology and Oncology</i> , <b>2011</b> , 28, 539-55	1.7	8
28	A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study. <i>Blood</i> , <b>2020</b> , 136, 8-9	2.2	8
27	Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. <i>Scientific Reports</i> , <b>2019</b> , 9, 19704	4.9	8
26	Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET 12) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27539	3	8
25	Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1312-1321	21.7	8
24	Cellular immunotherapy strategies for Ewing sarcoma. <i>Immunotherapy</i> , <b>2014</b> , 6, 611-21	3.8	7
23	Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells. <i>Oncology Reports</i> , <b>2013</b> , 29, 2348-54	3.5	7
22	Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review. <i>BMC Cancer</i> , <b>2020</b> , 20, 16	4.8	7
21	Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in Europe. <i>Klinische Padiatrie</i> , <b>2015</b> , 227, 108-15	0.9	6
20	Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. <i>Oncolimmunology</i> , <b>2013</b> , 2, e26091	7.2	6
19	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. <i>Blood Advances</i> , <b>2021</b> , 5, 2901-2908	7.8	5
18	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2021</b> , 7,	5.6	4
17	Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050). <i>ESMO Open</i> , <b>2021</b> , 6, 100250	6	4
16	Surface expression of the immunotherapeutic target G in osteosarcoma depends on cell confluency. <i>Cancer Reports</i> , <b>2021</b> , 4, e1394	1.5	3

15	Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML. <i>Blood Advances</i> , <b>2021</b> , 5, 4413-4421	7.8	3
14	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. <i>European Journal of Cancer</i> , <b>2021</b> ,	7.5	2
13	SIRPβ-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	2
12	Sequential acquisition of IgH and TCR rearrangements during the preleukemic phase of acute lymphoblastic leukemia in an adolescent patient. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 56, 301-3	3	1
11	Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies. <i>Oncot Immunology</i> , <b>2012</b> , 1, 358-360	7.2	1
10	T-Cells Redirected Against the kappa Light Chain of Human Immunoglobulins Target Mature B Cell Derived Malignancies In Vitro and In Vivo.. <i>Blood</i> , <b>2005</b> , 106, 612-612	2.2	1
9	Generation of an NFβ-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 751138	8.4	1
8	HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
7	Redirecting T cells to treat solid pediatric cancers. <i>Cancer and Metastasis Reviews</i> , <b>2019</b> , 38, 611-624	9.6	1
6	Akute Leukämien bei Kindern und Jugendlichen. <i>Monatsschrift Fur Kinderheilkunde</i> , <b>2009</b> , 157, 695-705	0.2	0
5	GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD and Releasing Inducible IL-18.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 839783	8.4	0
4	Akute Leukämien bei Kindern und Jugendlichen. <i>Best Practice Onkologie</i> , <b>2009</b> , 4, 26-34	0	
3	T-Zell-Therapien bei Leukämie. <i>Monatsschrift Fur Kinderheilkunde</i> , <b>2010</b> , 158, 232-239	0.2	
2	Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , <b>2003</b> , 151, 646-653	0.2	
1	Functional Consequences of TCAB1 Mutations in Dyskeratosis Congenita. <i>Blood</i> , <b>2016</b> , 128, 3890-3890	2.2	